Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-101 in Advanced or Metastatic Solid Tumors That Express Nectin-4
NCT06220838Phase 1Recruiting
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Allosteric Modulators, PROTACs (E3 ligase recruitment), Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-101 in solid tumor, sponsored by Tianjin ConjuStar Biologics Co., Ltd. Primary endpoints: Incidence of adverse events and Objective response rate. Started Feb 2024; status: recruiting.
02
Drugs
SC-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06220838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220838.